-
Mashup Score: 9Patient-Reported Outcomes Underutilized in GU Cancer Clinical Trials | GU Oncology Now - 3 month(s) ago
Despite GU cancers encompassing some of the most common diseases, the quality of PRO analyses over the past 15 years is unknown, as reporting has waned.
Source: guoncologynow.comCategories: General Medicine News, Partners & KOLsTweet
-
Mashup Score: 2Overview - OncLive® Fellows Forum - 7 month(s) ago
OncLive® is proud to present the National Fellows Forum, a series offered within breast cancer, genitourinary cancer, gynecologic oncology, hematologic malignancies, lung cancer, and precision medicine. These Forums provide the opportunity for fellows to share their current research and education with peers and role models within the oncology community. A board of esteemed faculty, within each…
Source: event.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#OncologyFellows, the deadline to submit your #GUCancer abstract is November 15th. Selected fellows will join us in San Francisco, CA this January for a complimentary 1-day trip of learning and networking! @DrChoueiri Submit: https://t.co/Mb3y8pwJx5 https://t.co/z7QA4tVFHk
-
-
Mashup Score: 1Overview - OncLive® Fellows Forum - 7 month(s) ago
OncLive® is proud to present the National Fellows Forum, a series offered within breast cancer, genitourinary cancer, gynecologic oncology, hematologic malignancies, lung cancer, and precision medicine. These Forums provide the opportunity for fellows to share their current research and education with peers and role models within the oncology community. A board of esteemed faculty, within each…
Source: event.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#OncologyFellows, the deadline to submit your #GUCancer abstract is November 15th. Selected fellows will join us in San Francisco, CA this January for a complimentary 1-day trip of learning and networking! @DrChoueiri Submit Abstract: https://t.co/WKABsPlXBm https://t.co/nnzg3ZPoch
-
-
Mashup Score: 0Overview - OncLive® Fellows Forum - 7 month(s) ago
OncLive® is proud to present the National Fellows Forum, a series offered within breast cancer, genitourinary cancer, gynecologic oncology, hematologic malignancies, lung cancer, and precision medicine. These Forums provide the opportunity for fellows to share their current research and education with peers and role models within the oncology community. A board of esteemed faculty, within each…
Source: event.onclive.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#OncologyFellows, get involved in research, education, & networking with your peers! Submit your #GUCancer abstract before November 15th. 25-30 Fellows will be selected to join us in San Francisco, CA in January! Submit Abstract: https://t.co/WKABsPlXBm https://t.co/lZ1swcbbEl
-
-
Mashup Score: 0VJOncology – The video journal of oncology - 7 month(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 September is Urological Cancer Awareness Month Check out https://t.co/ys1d8pDAKO to see our extensive coverage of #GUCancer, such as our interview with @PBarataMD on future approaches in #prostatecancer 🎥 👉 https://t.co/ypRuITaSTL #Oncology #GUsm #PCsm #uroonc https://t.co/W1odu87TsU
-
-
Mashup Score: 1Exclusive highlights in genitourinary cancer at ASCO 2023 - 8 month(s) ago
Pedro Barata, MD, University Hospitals Seidman Cancer Center, Cleveland, OH, provides important updates in genitourinary cancer at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress, including findings from the PEACE-1 trial (NCT01957436), as well as updates in PARP inhibitors with radioligands in prostate cancer. Dr Barata additionally comments on trials assessing salvage chemotherapy in renal cell carcinoma (RCC) and targeting EGFR in bladder cancer. This interview took place at the ASCO 2023 Annual Congress in Chicago, IL. These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Did you know that September is Urological Cancer Awareness Month? 🤔 Check out this interview from our #GUCancer channel with @PBarataMD, where he discusses highlights in #genitourinarycancer at #ASCO23 👉 https://t.co/QELNE442c5 #GUsm #PCsm #uroonc https://t.co/ZMRsMXHdJd
-
-
Mashup Score: 0VJOncology – The video journal of oncology - 8 month(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
📣 September is Urological Cancer Awareness Month! Check out https://t.co/ys1d8pDAKO to see our extensive coverage of #GUCancer, such as our interview with @RavimadanDr on #prostatecancer during #ASCO23 👉 https://t.co/2n9pL8SB1C #GUsm #PCsm #uroonc https://t.co/8zrlL0Nn6U
-
-
Mashup Score: 0VJOncology – The video journal of oncology - 8 month(s) ago
The Video Journal of Oncology (VJOncology) is an independent, global, open-access video journal, dedicated to providing trusted and up-to-date information in order to improve the awareness and understanding of oncology
Source: www.vjoncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Did you know that September is Urological Cancer Awareness Month? 🤔 Visit https://t.co/ys1d8pDAKO for the latest in #GUCancer, such as our interview with @TiansterZhang on #ADCs in #BladderCancer and #ProstateCancer! 👉 https://t.co/3TSKtDngZj #Oncology #GUsm #PCsm #uroonc https://t.co/sGBqLc4Ud5
-
-
Mashup Score: 2First-line combination demonstrates durable benefit in advanced urothelial carcinoma - 11 month(s) ago
CHICAGO — First-line enfortumab vedotin-ejfv plus pembrolizumab conferred promising long-term outcomes for cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma, study results presented at ASCO Annual Meeting showed.After median follow-up of nearly 4 years, researchers reported median response duration of more than 22 months and median OS of more than 26
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Enfortumab vedotin-ejfv plus pembrolizumab induced durable responses in cisplatin-ineligible urothelial carcinoma. We spoke with @shilpaonc of @ClevelandClinic to learn more. #ASCO23 #GUcancer @AstellasUS @SeattleGenetics https://t.co/eFeTJNC5pT
-
-
Mashup Score: 4Hot Seat: Maximizing PARP Inhibitors in CRPC - PER Updates from the Annual Oncology Meeting - 11 month(s) ago
PER Updates from the Annual Oncology Meeting.
Source: event.gotoper.comCategories: Hem/Oncs, Latest HeadlinesTweet-
Don’t miss my lecture during the PER symposium on maximizing PARP inhibitors in patients with CRPC at the annual oncology meeting in Chicago on June 4! Sign up today! https://t.co/WGCyRouKQ9 #GUcancer #gotoPER https://t.co/AyUSuV34xe
-
New research from @JadChahoud and colleagues revealed that patient-reported outcomes are currently underutilized in #GUCancer clinical trials. Learn more: https://t.co/3GkTCvAI6C https://t.co/tIKVR36wIY